Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotechnologies Raises $4.7M

NEW YORK (GenomeWeb News) – Diagnostics development firm Nuclea Biotechnologies has closed on a $4.7 million Series B financing round, its President and CEO confirmed to GenomeWeb Daily News.

Patrick Muraca said that the funds will be used for submission of its serum-based fatty acid synthase diagnostic test for prostate cancer to the US Food and Drug Administration for 510(k) clearance. Nuclea anticipates it will submit its application by the end of September, he said.

Muraca declined to identify the participants in the round.

The $4.7 million included $3.5 million in cash and $1.2 million in equity.

The financing was disclosed in a document filed with the US Securities and Exchange Commission on Thursday.

Based in Pittsfield, Mass., Nuclea develops gene, protein, and antibody biomarkers and pharmacogenetic diagnostic assays for predicting effective treatments for certain patients. A month ago, it and Clark University created a new center to use proteomic and metabolomic methods to conduct biomarker research directed at cancer.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.